CSL-111

is reconstituted HDL consisting of apolipoprotein A-I from human plasma combined with soybean phosphatidylcholine and chemically and biologically resembles native HDL

Networked: 3 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Tardif, Jean-Claude: 2 articles (09/2010 - 04/2007)
2.	Bringart, Matthieu: 1 article (01/2020)
3.	Couret, David: 1 article (01/2020)
4.	Denamur, Erick: 1 article (01/2020)
5.	Duranteau, Jacques: 1 article (01/2020)
6.	Genève, Claire: 1 article (01/2020)
7.	Louedec, Liliane: 1 article (01/2020)
8.	Meilhac, Olivier: 1 article (01/2020)
9.	Montravers, Philippe: 1 article (01/2020)
10.	Planesse, Cynthia: 1 article (01/2020)

Related Diseases

1.	Atherosclerotic Plaque (Atheroma) 09/01/2010 - "Among the 136 patients with evaluable end point data, percent change in atheroma volume, the primary endpoint, improved significantly in the CSL-111 group but not in the placebo group. " 04/18/2007 - "The percentage change in atheroma volume was -3.4% with CSL-111 and -1.6% for placebo (P = .48 between groups, P<.001 vs baseline for CSL-111). "
2.	Sepsis (Septicemia) 01/01/2020 - "CSL-111 infusion improved survival in different experimental mouse models of sepsis. " 01/01/2020 - "CSL-111 or saline solution was administrated 2 h after the sepsis. "
3.	Atherosclerosis 09/01/2010 - "In a larger trial, the Effect of rHDL on Atherosclerosis-Safety and efficacy (ERASE), 183 post-ACS patients were randomized to 4 weekly infusions of placebo or one of two doses of CSL-111, which consists of apoA-1 derived from human plasma and combined with soybean phosphatidylcholine. "
4.	Pneumonia (Pneumonitis) 01/01/2020 - "In the pneumonia model, fewer bacteria accumulated in liver and lung of the CSL-111 group. "

Related Drugs and Biologics

1.	Apolipoprotein A-I (Apolipoprotein A1)
2.	Phosphatidylcholines (Phosphatidylcholine)
3.	Saline Solution